Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice

Autoimmunity Reviews

Volumn 14, Issue 6, 2015, Pages 503-509

  Cantini, Fabrizio ^a   Nannini, Carlotta ^a   Niccoli, Laura ^a   Iannone, Florenzo ^b   Delogu, Giovanni ^c   Garlaschi, Giacomo ^d   Sanduzzi, Alessandro ^e   Matucci, Andrea ^f   Prignano, Francesca ^g   Conversano, Michele ^h   Goletti, Delia ⁱ  

^a Hospital of Prato   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f CAREGGI UNIVERSITY HOSPITAL   (Italy)

^g UNIVERSITY OF FLORENCE   (Italy)

^h Local Health ^*  (Italy)

ⁱ NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Ankylosing spondylitis; Biologics; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Tuberculosis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; BIOLOGICAL THERAPY; CLINICAL PRACTICE; DERMATOLOGY; DISEASE COURSE; EVIDENCE BASED PRACTICE; HUMAN; INFECTION PREVENTION; LATENT TUBERCULOSIS; PATIENT CARE; PATIENT MONITORING; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SCREENING; ANTAGONISTS AND INHIBITORS; COMPLICATION; RISK FACTOR; SKIN DISEASE;

ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; HUMANS; LATENT TUBERCULOSIS; RISK FACTORS; SKIN DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84933678868     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.01.011     Document Type: Review

References (71)

1. Arkema E.V., Jonsson J., Baecklund E., Bruchfeld J., Feltelius N., Askling J., et al. Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?. Ann Rheum Dis 2014, [Mar 7; (Epub ahead of print)].
2. Souto A., Maneiro J.R., Salgado E., Carmona L., Gomez-Reino J.J. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford) 2014, [May 11 (Epub ahead of print)].
3. Iannone F., Cantini F., Lapadula G. Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients on biologic therapy: the international recommendations. J Rheumatol Suppl 2014, 91:41-46.
4. Beglinger C., Dudler J., Mottet C., Nicod L., Seibold F., Villiger P.M., et al. Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med Wkly 2007, 137:620-622.
5. Solovic I., Sester M., Gomez-Reino J.J., Rieder H.L., Ehlers S., Milburn H.J., et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010, 36:1185-1206.
6. Singh J.A., Furst D.E., Bharat A., Curtis J.R., Kavanaugh A.F., Kremer J.M., et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012, 64:625-639.
7. Jensen P.A., Lambert L.A., Iademarco M.F., Ridzon R. CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings. MMWR Recomm Rep 2005, 54(RR-17):1-141. [Dec 30].
8. Goletti D., Sanduzzi A., Delogu G. Performance of the tuberculin skin test and interferon-γ release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approaches. J Rheumatol Suppl 2014, 91:24-31.
9. Piccazzo R., Paparo F., Garlaschi G. Diagnostic accuracy of chest radiography for the diagnosis of tuberculosis (TB) and its role in the detection of latent TB infection: a systematic review. J Rheumatol Suppl 2014, 91:32-40.
10. Bocchino M., Matarese A., Sanduzzi A. Current treatment options for latent tuberculosis infection. J Rheumatol Suppl 2014, 91:71-77.
11. Diel R., Goletti D., Ferrara G., Bothamley G., Cirillo D., Kampmann B., et al. Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011, 37:88-99.
12. Girardi E., Angeletti C., Puro V., Sorrentino R., Magnavita N., Vincenti D., et al. Estimating diagnostic accuracy of tests for latent tuberculosis infection without a gold standard among healthcare workers. Euro Surveill 2009, 14(43). [pii: 19373].
13. Costantino F., de Carvalho Bittencourt M., Rat A.C., Loeuille D., Dintinger H., Béné M.C., et al. Screening for latent tuberculosis infection in patients with chronic inflammatory arthritis: discrepancies between tuberculin skin test and interferon-γ release assay results. J Rheumatol 2013, 40:1986-1993.
14. Sester M., van Leth F., Bruchfeld J., Bumbacea D., Cirillo D.M., Dilektasli A.G., et al. Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. Am J Respir Crit Care Med 2014, 190:1168-1176.
15. Kim H.C., Jo K.W., Jung Y.J., Yoo B., Lee C.K., Kim Y.G., et al. Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay. Scand J Infect Dis 2014, 46:763-769.
16. O'Shea M.K., Fletcher T.E., Beeching N.J., Dedicoat M., Spence D., McShane H., et al. Tuberculin skin testing and treatment modulates interferon-gamma release assay results for latent tuberculosis in migrants. PLoS ONE 2014, 9:e97366.
17. Leung C.C., Rieder H.L., Lange C., Yew W.W. Treatment of latent infection with Mycobacterium tuberculosis: update 2010. Eur Respir J 2011, 37:690-711.
18. Yew W.W., Lange C., Leung C.C. Treatment of tuberculosis: update 2010. Eur Respir J 2011, 37:441-462.
19. Goletti D., Parracino M.P., Butera O., Bizzoni F., Casetti R., Dainotto D., et al. Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study. Respir Res 2007, 8:5.
20. Lo Bue P., Menzies D. Treatment of latent tuberculosis infection: an update. Respirology 2010, 15:603-622.
21. Carmona L., Hernández-García C., Vadillo C., Pato E., Balsa A., González-Alvaro I., et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003, 30:1736-1739.
22. Seong S.S., Choi C.B., Woo J.H., Bae K.W., Joung C.L., Uhm W.S., et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007, 34:706-711.
23. Brassard P., Lowe A.M., Bernatsky S., Kezouh A., Suissa S. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum 2009, 61:300-304.
24. Ramagopalan S.V., Goldacre R., Skingsley A., Conlon C., Goldacre M.J. Associations between selected immune-mediated diseases and tuberculosis: record-linkage studies. BMC Med 2013, 4(11):97.
25. Smolen J.S., Landewé R., Breedveld F.C., Buch M., Burmester G., Dougados M., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014, 73:492-509.
26. American Academy of Dermatology Work Group, Menter A., Korman N.J., Elmets C.A., Feldman S.R., Gelfand J.M., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011, 65:137-174.
27. Braun J., van den Berg R., Baraliakos X., Boehm H., Burgos-Vargas R., Collantes-Estevez E., et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011, 70:896-904.
28. Cline J.C., Davis S.M. Risks of infection or reactivation of tuberculosis associated with chronic corticosteroid therapy. Ann Pharmacother 1997, 31:775-776.
29. Jick S.S., Lieberman E.S., Rahman M.U., Choi H.K. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006, 55:19-26.
30. Cantini F., Niccoli L., Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol Suppl 2014, 91:47-55.
31. Elkayam O., Pavelka K. Biologic registries in rheumatology: lessons learned and expectations for the future. Autoimmun Rev 2012, 12:329-336.
32. Smolen J.S., Emery P., Fleischmann R., van Vollenhoven R.F., Pavelka K., Durez P., et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet 2014, 383(9914):321-332.
33. Schiff M., Weinblatt M.E., Valente R., van der Heijde D., Citera G., Elegbe A., et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 2014, 73:86-94.
34. Huang F., Gu J., Zhu P., Bao C., Xu J., Xu H., et al. Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial. Ann Rheum Dis 2014, 73:587-594.
35. Sieper J., Lenaerts J., Wollenhaupt J., Rudwaleit M., Mazurov V.I., Myasoutova, et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, part 1. Ann Rheum Dis 2014, 73:101-107.
36. Keystone E., Landewé R., van Vollenhoven R., Combe B., Strand V., Mease P., et al. Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension. Ann Rheum Dis 2014, 73:2094-2100.
37. Keystone E.C., Genovese M.C., Hall S., Miranda P.C., Bae S.C., Palmer W., et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2years of the GO-FORWARD study extension. J Rheumatol 2013, 40:1097-1103.
38. Emery P., Fleischmann R.M., Doyle M.K., Strusberg I., Durez P., Nash P., et al. Golimumab, a human anti-tumor necrosis factor monoclonal antibody, injected subcutaneously every 4weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Care Res (Hoboken) 2013, 65:1732-1742.
39. Weinblatt M.E., Westhovens R., Mendelsohn A.M., Kim L., Lo K.H., Sheng S., et al. Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial. Ann Rheum Dis 2014, 73:2152-2159.
40. Yoo D.H., Hrycaj P., Miranda P., Ramiterre E., Piotrowski M., Shevchuk S., et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013, 72:1613-1620.
41. Park W., Hrycaj P., Jeka S., Kovalenko V., Lysenko G., Miranda P., et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013, 72:1605-1612.
42. Fiorino G., Girolomoni G., Lapadula G., Orlando A., Danese S., Olivieri I., et al. The use of biosimilars in immune-mediated disease: a joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. Autoimmun Rev 2014, 13:751-755.
43. Lorenzetti R., Zullo A., Ridola L., Diamanti A.P., Laganà B., Gatta L., et al. Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials. Ann Med 2014, 46:547-554.
44. Cantini F., Niccoli L., Goletti D. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registries. J Rheumatol Suppl 2014, 91:56-64.
45. Payet S., Soubrier M., Perrodeau E., Bardin T., Cantagrel A., Combe B., et al. Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French Society of Rheumatology registry. Arthritis Care Res (Hoboken) 2014, 66:1289-1295.
46. Buch M.H., Smolen J.S., Betteridge N., Breedveld F.C., Burmester G., Dörner T., et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011, 70:909-920.
47. Cantarini L., Lopalco G., Caso F., Costa L., Iannone F., Lapadula G., et al. Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease. Autoimmun Rev 2015, 14:1-9.
48. Gabay C., Emery P., van Vollenhoven R., Dikranian A., Alten R., Pavelka K., et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013, 381(9877):1541-1550.
49. Burmester G.R., Rubbert-Roth A., Cantagrel A., Hall S., Leszczynski P., Feldman D., et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 2014, 73:69-74.
50. Ogata A., Tanimura K., Sugimoto T., Inoue H., Urata Y., Matsubara T., et al. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014, 66:344-354.
51. Koike T., Harigai M., Inokuma S., Ishiguro N., Ryu J., Takeuchi T., et al. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol 2014, 41:15-23.
52. Dougados M., Kissel K., Conaghan P.G., Mola E.M., Schett G., Gerli R., et al. Clinical, radiographic and immunogenic effects after 1year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis 2014, 73:803-809.
53. Kivitz A., Olech E., Borofsky M., Zazueta B.M., Navarro-Sarabia F., Radominski S.C., et al. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014, 66:1653-1661.
54. Takahashi N., Kojima T., Kaneko A., Kida D., Hirano Y., Fujibayashi T., et al. Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity. Clin Rheumatol 2014, 33:39-47.
55. Nüßlein H.G., Alten R., Galeazzi M., Lorenz H.M., Boumpas D., Nurmohamed M.T., et al. Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. BMC Musculoskelet Disord 2014, 15:14.
56. Westhovens R., Kremer J.M., Emery P., Russell A.S., Alten R., Barré E., et al. Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 7-year extended study. Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 7-year extended study. Clin Exp Rheumatol 2014, 32:553-562.
57. McInnes I.B., Kavanaugh A., Gottlieb A.B., Puig L., Rahman P., Ritchlin C., et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013, 382(9894):780-789.
58. Reich K., Puig L., Paul C., Kragballe K., Luger T., Lambert J., et al. One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis. Br J Dermatol 2014, 170:435-444.
59. Ritchlin C., Rahman P., Kavanaugh A., McInnes I.B., Puig L., Li S., et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014, 73:990-999.
60. Lin P.L., Dartois V., Johnston P.J., Janssen C., Via L., Goodwin M.B., et al. Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Proc Natl Acad Sci U S A 2012, 109:14188-14193.
61. Gómez-Reino J.J., Carmona L., Angel Descalzo M., Biobadaser Group Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007, 57:756-761.
62. Zink A., Manger B., Kaufmann J., Eisterhues C., Krause A., Listing J., et al. Evaluation of the RABBIT Risk Score for serious infections. Ann Rheum Dis 2014, 73:1673-1676.
63. Maksymowych W.P., Jhangri G.S., Fitzgerald A.A., LeClercq S., Chiu P., Yan A., et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60mg versus 10mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002, 46:766-773.
64. Viapiana O., Gatti D., Idolazzi L., Fracassi E., Adami S., Troplini S., et al. Bisphosphonates vs infliximab in ankylosing spondylitis treatment. Rheumatology (Oxford) 2014, 53:90-94.
65. Migliori G.B., Zellweger J.P., Abubakar I., Ibraim E., Caminero J.A., De Vries G., et al. European union standards for tuberculosis care. Eur Respir J 2012, 39:807-819.
66. Cantini F., Prignano F., Goletti D. Restarting biologics and management of patients with flares of inflammatory rheumatic disorders or psoriasis during active tuberculosis treatment. J Rheumatol Suppl 2014, 91:78-82.
67. Van Gestel A.M., Haagsma C.J., Van Riel P.L.C.M. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998, 41:1845-1850.
68. Machado P., Landewé R., Lie E., et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011, 70:47-53.
69. Fredriksson T., Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978, 157:238-244.
70. Ledingham J., Wilkinson C., Deighton C. British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-α treatments. Rheumatology (Oxford) 2005 Oct, 44(10):1205-1206.
71. Denis B., Lefort A., Flipo R.M., Tubach F., Lemann M., Ravaud P., et al. Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-alpha antagonist therapy: safe re-initiation of TNF-alpha blockers after appropriate anti-tuberculous treatment. Clin Microbiol Infect 2008 Feb, 14(2):183-186.